Peritoneal Carcinomatosis: Drugs and Diseases
(Sprache: Englisch)
The unique pharmacology that has been observed with the intraperitoneal administration of chemotherapy has generated considerable interest. The pharmacology of the drugs most likely to be employed as agents for intraperitoneal chemotherapy are presented....
Leider schon ausverkauft
versandkostenfrei
Buch
319.93 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Peritoneal Carcinomatosis: Drugs and Diseases “
Klappentext zu „Peritoneal Carcinomatosis: Drugs and Diseases “
The unique pharmacology that has been observed with the intraperitoneal administration of chemotherapy has generated considerable interest. The pharmacology of the drugs most likely to be employed as agents for intraperitoneal chemotherapy are presented. Progress in peritoneal carcinomatosis has been slow in the past because clinicians attempted to accomplish the impossible. Advanced disease was treated with intraperitoneal chemotherapy or immunotherapy. Heterogeneous responses were seen, but complete eradication of disease was impossible. No treatments described to date can penetrate deeply enough into established tumour modules to confer lasting benefit. To make matters worse, the chemotherapy was almost always used in an abdomen or pelvis that had been treated by prior surgery. Scar tissue makes uniform distribution of chemotherapy impossible. These two conditions meant that patients showed little long-term benefit.
Peritoneal Carcinomatosis: Drugs and Diseases , a collection of old diseases and new concepts, will stimulate work in this field, conferring benefits in terms of quality of life and survival on cancer patients.
Inhaltsverzeichnis zu „Peritoneal Carcinomatosis: Drugs and Diseases “
- Foreword; A. Cohen. Preface; P.H. SugarbakerSection I: Pharmacology
1. Intraperitoneal taxol; M. Markman
2. Early postoperative intraperitoneal adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma; P.H. Sugarbaker
3. Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis; A. Stephens, et al.
4. Intraperitoneal regional chemotherapy with mitoxantrone; K. Link, et al.
5. Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin; H.R. Alexander, D.L. Fraker
6. Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C; V. Fernandez-Trigo, et al.
Section II: Disease states
7. Pathobiology of peritoneal carcinomatosis from ovarian malignancy; T.A. Sugarbaker, et al.
8. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent rectosigmoid cancer; P.H. Sugarbaker
9. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy; P.H. Sugarbaker
10. Pseudomyxoma peritonei; P.H. Sugarbaker
11. Clinical determinants of treatment failures after cytoreductive surgery and intraperitoneal chemotherapy in patients with pseudomyxoma peritonei; V. Fernandez-Trigo, et al.
12. Recurrent intraabdominal cancer causing intestinal obstruction: Washington Hospital Center experience with 42 patients managed by surgery and intraperitoneal chemotherapy; A.M. Averbach, P.H. Sugarbaker
13. Peritoneal carcinomatosis: Natural history and rational therapeutic interventions using intraperitoneal chemotherapy; P.H. Sugarbaker
14. Survival time and prevention of side effects of intraperitoneal hyperthermic perfusion with mitomycin c combined with surgery for patients with advanced gastric cancer; S. Fujimoto, et al.
15. Intraperitoneal 5-fluoracil and mitomycin c as an adjuvant
... mehr
to resectable gastric cancer: a status report; W. Yu
16. Mechanism and treatment of peritoneal carcinomatosis: Intraperitoneal chemotherapy with mitomycin c bound to carbon particles; T. Takahashi, et al.
17. Peritoneal mesothelioma: treatment approach based on natural history; A.M. Averbach, P.H. Sugarbaker
- Pathology of peritoneal mesothelioma; M.E. Kass
- Rationale for intraperitoneal chemotherapy in the treatment of adenocarcinoma of the pancreas; S.E. Ettinghausen
- Heated intraperitoneal mitomycin c infusion treatment for patients with gastric cancer and peritoneal metastasis; S. Fujimoto, et al.
- Peritoneal carcinomatosis from adenocarcinoma of the colon; M.E.T. Schellinx, et al.
16. Mechanism and treatment of peritoneal carcinomatosis: Intraperitoneal chemotherapy with mitomycin c bound to carbon particles; T. Takahashi, et al.
17. Peritoneal mesothelioma: treatment approach based on natural history; A.M. Averbach, P.H. Sugarbaker
- Pathology of peritoneal mesothelioma; M.E. Kass
- Rationale for intraperitoneal chemotherapy in the treatment of adenocarcinoma of the pancreas; S.E. Ettinghausen
- Heated intraperitoneal mitomycin c infusion treatment for patients with gastric cancer and peritoneal metastasis; S. Fujimoto, et al.
- Peritoneal carcinomatosis from adenocarcinoma of the colon; M.E.T. Schellinx, et al.
... weniger
Bibliographische Angaben
- 1996, 288 Seiten, 3 farbige Abbildungen, Maße: 16 x 24,1 cm, Gebunden, Englisch
- Herausgeber: Sugarbaker, Paul H.
- Herausgegeben: Paul H. Sugarbaker
- Verlag: Springer
- ISBN-10: 0792337263
- ISBN-13: 9780792337263
- Erscheinungsdatum: 29.02.1996
Sprache:
Englisch
Kommentar zu "Peritoneal Carcinomatosis: Drugs and Diseases"
0 Gebrauchte Artikel zu „Peritoneal Carcinomatosis: Drugs and Diseases“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Peritoneal Carcinomatosis: Drugs and Diseases".
Kommentar verfassen